Trial
NCT04128696
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
Merck Sharp & Dohme LLC
Condition
Neoplasms, Head and Neck
Intervention
feladilimab
Why stopped
The trial was stopped by the sponsor based on assessment of the clinical data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-10